Musculoskeletal Disorders

Edgewise reports data from trial of muscular dystrophy drug

US-based biotechnology company Edgewise Therapeutics has reported positive two-year topline data from the ARCH clinical trial of sevasemten (EDG-5506) in…

Atamyo obtains clearance for muscular dystrophy gene therapy trial in Europe

Atamyo Therapeutics has received regulatory clearance in Europe to initiate a Phase Ib clinical trial for its gene therapy, ATA-200,…

NMD Pharma gets FDA IND clearance for Phase IIb gMG treatment trial

NMD Pharma has secured clearance for an Investigational New Drug (IND) application from the US Food and Drug Administration to…

Avidity accelerates DM1 Phase III trial on the heels of further positive data

Avidity Biosciences has accelerated the initiation of its Phase III trial in myotonic dystrophy type 1 (DM1) after announcing further…

J&J touts success of nipocalimab in two rare disease trials

Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…

Rise Therapeutics begins rheumatoid arthritis therapy trial

US-based biotechnology company Rise Therapeutics has enrolled the first subject in its Phase I clinical trial of R-2487, a new…

Sarepta begins screening in muscular dystrophy gene therapy trial

Sarepta Therapeutics has commenced subject screening for its Phase III EMERGENE clinical trial (Study SRP-9003-301) of investigational gene therapy SRP-9003…

Avenue concludes subject enrolment in SBMA treatment trial

Avenue Therapeutics has completed subject enrolment in the Phase Ib/IIa clinical trial of its new drug candidate, AJ201, to treat…

Lynk commences Phase III rheumatoid arthritis drug trial

Lynk Pharmaceuticals has dosed the first subject in a Phase Ⅲ clinical trial of its JAK1 inhibitor, LNK01001, to treat…

Reneo cuts 70% of staff following Phase III trial failure

US-based Reneo Pharmaceuticals has plans to institute cost-saving initiatives, including a workforce reduction by 70%, after its lead candidate mavodelpar…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close